The Committee for Medicinal Products for Human Use (CHMP) is responsible for the scientific evaluation of the application dossier on the quality, efficacy and safety (including environmental safety) of the medicinal product as part of the centralized marketing authorization procedure for new medicinal products. The CHMP's scientific assessment report forms the basis for the European Commission's decision to grant or refuse a central marketing authorization for a medicinal product for human use.

The CHMP is composed of scientists from all member states of the European Economic Area (EEA). More information on the Committee for Medicinal Products for Human Use can be found on the website of the European Medicines Agency (EMA). An overview of all centrally authorised medicinal products can be found in the Union Register of medicinal products for human use of the European Commission.

The CHMP member and alternate for Germany are:

CHMP Meeting Highlights - BfArM

With the CHMP Meeting Highlights we inform you monthly about marketing authorisation recommendations for new medicinal products, new indications for already approved medicinal products as well as the start of procedures for selected medicinal products in the European Union (EU).

Latest

In the month of May 2024, medicinal products for the following indications have received a positive opinion:

• Congenital thrombotic thrombocytopenic purpura
• Acanthamoeba keratitis
• Non-small cell lung cancer
• Haemophilia B
• Prophylaxis of influenza
• Radiolabelling for positron emission tomography (PET) imaging
• Prevention of disease caused by chikungunya virus (CHIKV)
• Severe hypoglycaemia in patients with diabetes mellitus

For more information, please refer to the CHMP Meeting Highlights for May 2024.

Previous CHMP Meeting Highlights